182 related articles for article (PubMed ID: 22735461)
1. Effect of food on the pharmacokinetics and pharmacodynamics of R1663, an oral factor Xa inhibitor, in healthy male volunteers.
Schmitt C; Charoin-Pannier A; McIntyre C; Zandt H; Ciorciaro C; Zweigler L; Winters K; Pepper T
Int J Clin Pharmacol Ther; 2012 Aug; 50(8):566-72. PubMed ID: 22735461
[TBL] [Abstract][Full Text] [Related]
2. Crossover dose escalation study to assess safety, pharmacokinetics, and pharmacodynamics of single doses of R1663, an oral factor Xa inhibitor, in healthy male volunteers.
Schmitt C; Pannier A; McIntyre C; Zandt H; Ciorciaro C; Winters K; Pepper T
J Clin Pharmacol; 2012 Apr; 52(4):499-510. PubMed ID: 21566199
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
[TBL] [Abstract][Full Text] [Related]
4. Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials.
Godfrey AR; Digiacinto J; Davis MW
Clin Ther; 2011 Jun; 33(6):766-75. PubMed ID: 21704241
[TBL] [Abstract][Full Text] [Related]
5. Safety, pharmacokinetics and pharmacodynamics of multiple ascending doses of R1663, an oral factor Xa inhibitor, in healthy young subjects coupled with exploration of influence of gender and age.
Schmitt C; Charoin-Pannier A; McIntyre C; Zandt H; Ciorciaro C; Winters K; Pepper T
Thromb Haemost; 2012 Jul; 108(1):54-64. PubMed ID: 22552265
[TBL] [Abstract][Full Text] [Related]
6. Lack of significant food effect on the pharmacokinetics of ticagrelor in healthy volunteers.
Teng R; Mitchell PD; Butler K
J Clin Pharm Ther; 2012 Aug; 37(4):464-8. PubMed ID: 21967645
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers.
Kapil R; Nolting A; Roy P; Fiske W; Benedek I; Abramowitz W
Clin Ther; 2004 Dec; 26(12):2015-25. PubMed ID: 15823765
[TBL] [Abstract][Full Text] [Related]
8. Effects of food intake on the pharmacokinetic properties of dalcetrapib: findings from three phase I, single-dose crossover studies in healthy volunteers.
Derks M; Kawamura H; Abt M; Meneses-Lorente G; Phelan M; Ishikawa T
Clin Ther; 2011 Jun; 33(6):754-65. PubMed ID: 21704240
[TBL] [Abstract][Full Text] [Related]
9. Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults.
Lee J; Zhang W; Moy S; Kowalski D; Kerbusch V; van Gelderen M; Sawamoto T; Grunenberg N; Keirns J
Clin Ther; 2013 Mar; 35(3):333-41. PubMed ID: 23497763
[TBL] [Abstract][Full Text] [Related]
10. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
[TBL] [Abstract][Full Text] [Related]
11. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
Feng L; Shen-Tu J; Liu J; Chen J; Wu L; Huang M
Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
[TBL] [Abstract][Full Text] [Related]
12. Bioavailability and bioequivalence of two oral formulations of alendronate sodium 70 mg: an open-label, randomized, two-period crossover comparison in healthy Korean adult male volunteers.
Rhim SY; Park JH; Park YS; Lee MH; Kim DS; Shaw LM; Yang SC; Kang JS
Clin Ther; 2009 May; 31(5):1037-45. PubMed ID: 19539104
[TBL] [Abstract][Full Text] [Related]
13. Single-dose relative bioavailability of a new quetiapine fumarate extended-release formulation: a postprandial, randomized, open-label, two-period crossover study in healthy Uruguayan volunteers.
Estevez-Carrizo FE; Parrillo S; Ercoli MC; Estevez-Parrillo FT
Clin Ther; 2011 Jun; 33(6):738-45. PubMed ID: 21704238
[TBL] [Abstract][Full Text] [Related]
14. A randomized study of the effects of food on the pharmacokinetics of once-daily extended-release hydromorphone in healthy volunteers.
Moore KT; St-Fleur D; Marricco NC; Ariyawansa J; Pagé V; Natarajan J; Morelli G; Richarz U
J Clin Pharmacol; 2011 Nov; 51(11):1571-9. PubMed ID: 21098692
[TBL] [Abstract][Full Text] [Related]
15. The minimal impact of food on the pharmacokinetics of ridaforolimus.
Stroh M; Li X; Marsilio S; Panebianco D; Johnson-Levonas A; Juan A; Orford K; Agrawal N; Trucksis M; Wagner JA; Murphy G; Iwamoto M
Cancer Chemother Pharmacol; 2012 Jul; 70(1):177-82. PubMed ID: 22669570
[TBL] [Abstract][Full Text] [Related]
16. Relative bioavailability of sapropterin from intact and dissolved sapropterin dihydrochloride tablets and the effects of food: a randomized, open-label, crossover study in healthy adults.
Musson DG; Kramer WG; Foehr ED; Bieberdorf FA; Hornfeldt CS; Kim SS; Dorenbaum A
Clin Ther; 2010 Feb; 32(2):338-46. PubMed ID: 20206791
[TBL] [Abstract][Full Text] [Related]
17. Bioavailability of a co-formulated combination of amodiaquine and artesunate under fed and fasted conditions. A randomised, open-label crossover study.
Fitoussi S; Thang C; Lesauvage E; Barré J; Charron B; Filali-Ansary A; Lameyre V
Arzneimittelforschung; 2009; 59(7):370-6. PubMed ID: 19728565
[TBL] [Abstract][Full Text] [Related]
18. A randomized, phase I, 3-way crossover study to examine the effects of food on the pharmacokinetics of single doses of 400 mg posaconazole oral suspension in healthy male Taiwanese subjects.
Lin TY; Yang MH; Chang FY
Ther Drug Monit; 2013 Apr; 35(2):223-7. PubMed ID: 23503449
[TBL] [Abstract][Full Text] [Related]
19. Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects.
Hauns B; Hermann R; Hünnemeyer A; Herzog R; Hauschke D; Zech K; Bethke TD
J Clin Pharmacol; 2006 Oct; 46(10):1146-53. PubMed ID: 16988203
[TBL] [Abstract][Full Text] [Related]
20. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects.
Frost C; Wang J; Nepal S; Schuster A; Barrett YC; Mosqueda-Garcia R; Reeves RA; LaCreta F
Br J Clin Pharmacol; 2013 Feb; 75(2):476-87. PubMed ID: 22759198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
